Thrivent Financial for Lutherans bought a new position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 973,713 shares of the company's stock, valued at approximately $43,992,000. Thrivent Financial for Lutherans owned 1.66% of Twist Bioscience as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Signaturefd LLC grew its holdings in Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after acquiring an additional 306 shares during the period. EdgeRock Capital LLC acquired a new stake in Twist Bioscience during the second quarter worth about $43,000. Blue Trust Inc. grew its holdings in Twist Bioscience by 2,912.8% during the second quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock worth $58,000 after acquiring an additional 1,136 shares during the period. DekaBank Deutsche Girozentrale acquired a new stake in Twist Bioscience during the second quarter worth about $61,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Twist Bioscience by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock valued at $98,000 after purchasing an additional 381 shares during the period.
Analyst Ratings Changes
A number of research firms have recently commented on TWST. Evercore ISI boosted their price objective on Twist Bioscience from $52.00 to $56.00 and gave the company an "outperform" rating in a research report on Tuesday, October 1st. JPMorgan Chase & Co. increased their price objective on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an "underweight" rating in a report on Monday, August 5th. Barclays cut their target price on shares of Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating for the company in a research note on Tuesday. Robert W. Baird raised their price target on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an "outperform" rating in a research note on Tuesday. Finally, Scotiabank boosted their price objective on Twist Bioscience from $50.00 to $54.00 and gave the stock a "sector outperform" rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $51.78.
Get Our Latest Report on TWST
Twist Bioscience Stock Down 1.4 %
Shares of Twist Bioscience stock traded down $0.57 on Tuesday, hitting $40.86. 537,961 shares of the company were exchanged, compared to its average volume of 950,628. The company has a 50-day moving average price of $43.98 and a 200 day moving average price of $46.18. The stock has a market capitalization of $2.39 billion, a price-to-earnings ratio of -10.74 and a beta of 1.78. Twist Bioscience Co. has a 1-year low of $23.00 and a 1-year high of $60.90.
Insider Buying and Selling
In other news, CAO Robert F. Werner sold 1,448 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $64,580.80. Following the sale, the chief accounting officer now owns 45,620 shares of the company's stock, valued at approximately $2,034,652. The trade was a 3.08 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Dennis Cho sold 1,507 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $48.00, for a total value of $72,336.00. Following the transaction, the insider now owns 91,163 shares of the company's stock, valued at approximately $4,375,824. This represents a 1.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 98,118 shares of company stock worth $4,391,151. 3.92% of the stock is owned by corporate insiders.
Twist Bioscience Profile
(
Free Report)
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
See Also
Before you consider Twist Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.
While Twist Bioscience currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
